OpportunityAnalyzer: Osteoarthritis Report - Opportunity Analysis and Forecasts to 2024 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "OpportunityAnalyzer: Osteoarthritis - Opportunity Analysis and Forecasts to 2024" drug pipelines to their offering.

Osteoarthritis space set to undergo radical changes, approaching $10.5 billion by 2024

The osteoarthritis market across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan is forecast to more than treble from $3.25 billion in 2014 to $10.49 billion by 2024, representing a compound annual growth rate of 17.8%.

The report states that this rapid growth can be attributed to the launch of new biologic therapies priced at a substantial premium to small-molecule therapies, the launch of drugs with novel mechanisms of action (MOAs) and disease-modifying effects, the growth of the osteoarthritis population, and recent improvements in imaging techniques to facilitate the development of disease-modifying osteoarthritis drugs.

New therapies include Invossa, a cell-based disease-modifying osteoarthritis drug, and sprifermin, a cytokine-based therapy. The rapid evolution of the osteoarthritis pipeline will lead to a shift toward novel analgesics and disease-modifying drugs in the treatment paradigm. In this way, the author anticipates that the osteoarthritis market landscape will change radically over the next 20 years.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

3.2 Symptoms

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.5 Epidemiological Forecast for OA (2014-2024)

4.6 Discussion

5 Current Treatment Options

5.1 Overview

5.2 Product Profiles - Major Therapies

6 Unmet Needs Assessment and Opportunity Analysis

6.1 Overview

6.2 Analgesic Drugs that Adequately Address Pain

6.3 Disease-Modifying Drugs

6.4 Drugs with Improved Tolerability for Use in the Elderly Patient Population

6.5 Improved Implementation of Guidelines on Non-pharmaceutical Treatments

6.6 Early Detection and Intervention

7 Research and Development Strategies

7.1 Overview

7.2 Development of Pharmacological Treatments with Novel MOAs

7.3 Development of Disease-Modifying OA Drugs

7.4 Strategic Partnerships

7.5 Current Clinical Trial Design

7.6 Future Clinical Trial Design

8 Pipeline Assessment

8.1 Overview

8.2 Promising Drugs in Clinical Development

8.3 Innovative Early-Stage Approaches

9 Pipeline Valuation Analysis

9.1 Clinical Benchmarking of Key Pipeline Drugs

9.2 Commercial Benchmark of Key Pipeline Drugs

9.3 Competitive Assessment

9.4 Top-Line 10-Year Forecast

10 Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/j74c79/opportunityanalyze

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Musculoskeletal Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Musculoskeletal Disorders Drugs